Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: ccRCC, RCC, Kidney Cancer, Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
Interventions: MK-3795, Nivolumab, Cabozantinib, Bezlutifan; Drug
Lead sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 25
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 18 more

Conditions: Healthy, Hepatic Impairment
Interventions: T-817MA; Drug
Lead sponsor: FUJIFILM Toyama Chemical Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Multiple Myeloma
Interventions: carfilzomib, pegylated liposomal doxorubicin (PLD), Dexamethasone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Other Specified Complications of Labor and Delivery
Interventions: Vaginal Delivery Debrief Checklist; Other
Lead sponsor: Providence Health & Services; Other
Eligibility: Not listed
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Olympia, Washington

Conditions: Infant, Premature, Diseases
Interventions: Multisensory early oral administration of human milk; Other
Lead sponsor: Loyola University; Other
Eligibility: 23 Weeks to 32 Weeks
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 2
States / cities: Maywood, Illinois

Conditions: Diabetes Mellitus, Type 1
Interventions: occupation-based coaching; Behavioral
Lead sponsor: Creighton University; Other
Eligibility: 2 Years to 12 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Restrictive Chronic Lung Allograft Dysfunction, Lung Transplant Rejection
Interventions: Pirfenidone; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pre-hypertension
Interventions: Heat & Aerobic Training (HEAT), Exercise Only; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 45 Years to 64 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Breast Cancer, Cancer of the Breast
Interventions: Cryoablation; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 98
States / cities: Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 84 more

Conditions: Ulcerative Colitis (UC)
Interventions: Placebo, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 1,302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 149
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 114 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H, Treatment I, Treatment J; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Neoplasms by Site
Interventions: nivolumab, rHuPH20; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 10
States / cities: Atlanta, Georgia • Rockville, Maryland • Detroit, Michigan + 7 more

Conditions: Brain Tumor
Interventions: [18F]FLT, [18F]Fluciclovine; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Mantle Cell Lymphoma
Interventions: R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Smoking Cessation, Obesity
Interventions: Self-Regulation strategies + large changes (SR), Healthy Lifestyle Education (LE), Smoking Cessation Treatment; Behavioral · Other
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Small Cell Lung Cancer
Interventions: SC-002; Drug
Lead sponsor: Stemcentrx; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 4
States / cities: Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 1 more

Conditions: Healthy Volunteer
Interventions: ANG-3777 (Therapeutic Dose), ANG-3777 (Supra-therapeutic Dose), Placebo, Moxifloxacin Hydrochloride; Drug
Lead sponsor: Angion Biomedica Corp; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Adult Influenza Vaccinations, Adult PPSV Vaccinations, Adult Tdap/Td Vaccinations
Interventions: Pillar 1: Convenient Vaccination Services, Pillar 2: Patient notification, Pillar 3: Enhanced Office Systems, Pillar 4: Motivation; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 70,549 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Houston, Texas

Conditions: Acute Phase Response
Interventions: Graded Exercise, Marathon participation; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 49 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Blood Draw, Lumbar Puncture; Procedure
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Focal Epilepsy
Interventions: BHV-7000, Placebo; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 44 more

Conditions: Macular Degeneration
Interventions: NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks; Drug
Lead sponsor: Neurotech Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 32
States / cities: Phoenix, Arizona • Beverly Hills, California • Irvine, California + 28 more

Conditions: Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
Interventions: Asynchronous, eLearning Intervention; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

PK Study of T-817 in Subjects With Hepatic Impairment

Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Vaginal Delivery Debrief Checklist to Improve Team Communication

Multisensory Early Oral Administration of Human Milk (M-MILK) for Very Preterm Infants

Telehealth Family Coaching With Type 1 Diabetes

Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction

Heat & Aerobic Training (HEAT) Study

COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors

Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma

A Multiple Health Behavior Change Intervention for Overweight and Obese Smokers

SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

SOP Toolkit in Diverse Practices Implemented & Tested With RE-AIM

Defining the Temporal Changes in the Acute Phase Response During Graded Exercise: A Prospective Study

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

HealthMatters@24/7 eLearning for People Supporting Adults With Intellectual and Developmental Disabilities